Background: Dietary and circulating carotenoids have been inversely associated with breast cancer risk, but observed associations may be due to confounding. Single-nucleotide polymorphisms (SNPs) in b-carotene 15,15 0 -monooxygenase 1 (BCMO1), a gene encoding the enzyme involved in the first step of synthesizing
Introduction
Inverse associations with breast cancer for dietary (1) and circulating (2) carotenoids have been observed in 2 pooled analyses of prospective studies. In particular, higher dietary intakes of a-, b-carotene, and lutein/zeaxanthin have been associated with lower risk of estrogen receptor-negative (ER À ) breast cancer, and dietary b-cryptoxanthin has been inversely associated with overall breast cancer risk (1) . Several circulating carotenoids have been inversely associated with breast cancer risk with stronger associations observed for a-and b-carotene and ER À breast cancer (2) . Together, these analyses suggest carotenoids may reduce breast cancer risk, and a-and b-carotene may be particularly protective against ER À breast cancer. The major carotenoids in the United States are a-, b-carotene, b-cryptoxanthin, lycopene, lutein, and zeaxanthin (3) (4) (5) . a-, b-Carotene, and b-cryptoxanthin are known as provitamin A carotenoids as they can be converted into retinal, retinol, and other forms of vitamin A. The first step of this conversion is central cleavage by b-carotene 15,15 0 -monooxygenase 1 (BCMO1; refs. 6-9). The resultant retinal, an active form of vitamin A, can be reduced to retinol and converted into retinyl esters, such as retinyl palmitate, for storage in the liver. For more detailed description of the carotenoid pathway, the reader is referred to Figure 3 in Ferrucci and colleagues (10) . It is difficult to disentangle potential causal mechanisms behind the observed associations between carotenoids and breast cancer. As the provitamin A carotenoids, including a-and b-carotene, can be converted to vitamin A, protective associations may be due to vitamin A or possibly other metabolic products. Indeed, dietary vitamin A has been weakly inversely associated with breast cancer (11) . However, given that more vitamin A activity comes from preformed vitamin A than from provitamin A carotenoids in the western diet, the effect of provitamin A carotenoids on breast cancer risk through their vitamin A activity is probably low.
Because fruits and vegetables are the primary source of carotenoids, both dietary and circulating carotenoids are associated with other phytochemicals and nutrients provided by these same foods. Fruit and vegetable intake is also inversely associated with lifestyle factors such as physical inactivity, smoking, and alcohol consumption (12) . These associations thus preclude causal attribution of the reduction in breast cancer risk to carotenoids in the pooled studies of dietary and circulating carotenoids described earlier. Mendelian Randomization offers one avenue for attempting to circumvent potential confounding (13) and could provide evidence that specific carotenoids are responsible for lower risk of breast cancer. The distribution of genetic polymorphisms is unlikely to be associated with behaviors (13) , such as diet and other lifestyle factors that could confound association with dietary and circulating carotenoids. When genetic variants alter the activity of an enzyme involved in nutrient metabolism, those variants can theoretically be used as proxies for different exposure levels of that nutrient (14) . Observed associations between the genetic variants and disease risk can thus provide additional evidence of a causal association between a given nutrient and disease risk.
Single-nucleotide polymorphisms (SNPs) in BCMO1 have been associated with circulating carotenoid levels and b-carotene conversion efficiency (10, 15, 16) . The rs12934922 T allele has been associated with both reduced conversion of b-carotene to retinyl palmitate as well as higher fasting plasma b-carotene (15) . The rs6564851 G allele was associated with increased circulating levels of a-and b-carotene and decreased levels of lycopene, lutein, and zeaxanthin in a previous genome-wide association study (GWAS; ref. 10) . This allele has also been reported to reduce BCMO1 activity (16) . In the Nurses' Health Study (NHS), both alleles were significantly associated with higher plasma provitamin A carotenoid concentrations, and the T allele for each SNP was associated with higher plasma lutein/zeaxanthin concentrations (17) . It is possible that SNPs in BCMO1 can reduce conversion efficiency to retinol, leading to higher provitamin A carotenoid exposure and theoretically lower retinol exposure. The non-provitamin A carotenoids are not known substrates for BCMO1 (8, 9) , and Hendrickson and colleagues did not observe associations between BCMO1 SNPs and plasma lycopene concentrations (17) . However, they did observe an association between BCMO1 SNPs and plasma lutein/ zeaxanthin concentrations and hypothesized that the observed association was due to either carotenoid interactions, altered b, b-carotete-9 0 ,10 0 -oxygenase (BCDO2) expression or as yet unknown direct activity of BCMO1 on lutein zeaxanthin.
Here, we assessed the association between SNPs in or near BCMO1 and breast cancer risk in the National Cancer Institute's (NCI) Breast and Prostate Cancer Cohort Consortium (BPC3). On the basis of our previous findings that SNPs in or near BCMO1 predict plasma carotenoid concentrations, we generated weighted multi-SNP scores. Our hypothesis was that the plasma carotenoid-weighted multi-SNP scores, which are positively associated with plasma carotenoid concentrations, are inversely associated with breast cancer risk. We also tested for possible interactions with menopausal status, smoking status, pack-years of smoking, alcohol intake, and body mass index (BMI).
Materials and Methods

Study population
Seven prospective cohorts from BPC3, which has been described elsewhere (18) 
Weighted multi-SNP scores
To test the hypothesis that carotenoids are causally associated with breast cancer risk, we generated multi-SNP scores for carotenoids and retinol based on our previous observations that BMCO1 SNPs are associated with circulating levels. On the basis of rs6564851 and rs12934922 genotypes, we created 5 separate weighted multi-SNP scores that were associated with plasma concentrations of a-, b-carotene, b-cryptoxanthin, lutein/ zeaxanthin, and retinol. We only included rs6564851 and rs12934922 in the multi-SNP score as they have been shown to predict the carotenoids considered here (10, (15) (16) (17) . In the weighted multi-SNP scores, the effect allele was defined as the allele associated with higher biomarker concentrations, and the weighted multi-SNP scores were calculated from the number of effect alleles weighted by each SNP's mutually adjusted association with the relevant plasma biomarker in the NHS. Weights for this analysis were derived among 2,579 NHS participants who were included in a previous analysis of the association between BCMO1 SNPs and plasma carotenoid and retinol concentrations (17) and for whom rs6564851 and rs12934922 were genotyped. Specifically, we used b-coefficients for each SNP when included simultaneously as additive independent variables (number of effect alleles) in multivariate linear regression models with the natural log-transformed biomarker concentration (mg/L) as the dependent variable. Models for each biomarker included age, case-control status, BMI, cholesterol, menopausal status and postmenopausal hormone use, smoking status, alcohol intake, energy-adjusted fat intake, energy-adjusted intake of the nutrient of interest, and, for the provitamin A carotenoids, energy-adjusted retinol intake (IU/d) as covariates. See ref. (17) for further detail. Separate models were run for a-, b-carotene, b-cryptoxanthin, lutein/zeaxanthin, and retinol. We calculated caroteniod-specific weights as follows: a-car-
. Because neither SNP was significantly associated with plasma lycopene concentrations, a weighted multi-SNP score was not derived for this biomarker. The weighted multi-SNP scores were divided into quintiles based on their distribution among BPC3 controls. Geometric mean plasma biomarker concentrations by weighted multi-SNP score quintiles for NHS subjects are shown in Supplementary Table S1 .
Statistical analysis
ORs and 95% confidence intervals (CI) were determined by unconditional logistic regression adjusted for study and 5-year age category at baseline or blood draw, depending on cohort. Multi-SNP score quintile indicator variables were included in the models with the lowest quintile as the reference category. Continuous weighted multi-SNP scores were used in tests for trend and interaction. We tested the individual SNPs by including indicator variables for heterozygous and homozygous variant genotypes in the models. For trend and interaction tests, SNPs were additively modeled. We also conducted subanalyses for ER þ , ER À , and ER À /PR À breast cancer risk, data for which were available in 67% to 76% of the cases. All reported P values are two-sided and not adjusted for number of tests conducted. P values less than 0.05 were considered statistically significant. All statistical analyses were conducted using SAS version 9 (SAS Institute).
P values for interactions were determined by likelihood ratio tests. Interaction cross-product terms were calculated as the weighted multi-SNP score or additive SNP genotype multiplied by indicators for menopausal status (postmenopausal/premenopausal) or smoking status (never/former or current) or by continuous measures of pack-years of smoking, BMI (kg/m 2 ), or alcohol intake (g/d). Models stratified by BMI (<25, !25-<30, and !30 kg/m 2 ) were adjusted for continuous BMI. Models stratified by alcohol intake (<1, !1 drink/d) were adjusted for continuous alcohol intake. Models stratified by packyears of smoking [0, <14.5 (the median among smokers), and !14.5 pack-years] were adjusted for continuous packyears. Women with implausible BMI (<16 or >55 kg/m 2 ; n ¼ 27) or alcohol intake (>100 g/d; n ¼ 17) were excluded from the respective interaction analyses. Interactions were not tested for ER À /PR À breast cancer due to concerns of limited power.
Expected ORs of breast cancer across extreme a-, b-carotene, b-cryptoxanthin, and lutein/zeaxanthinweighted multi-SNP score quintiles were determined from the association between each circulating carotenoid and breast cancer risk in the recent pooled analysis (2) and, using methods described in ref. (17), the association between each weighted multi-SNP score and plasma concentrations of the relevant carotenoid in the NHS. Expected ORs for retinol were not determined because the association between circulating retinol and risk of breast cancer was not assessed in the pooled analysis (2) . To account for attenuation of the circulating carotenoids and breast cancer OR that may occur from only having one plasma measurement per participant, the intraclass correlation (ICC) for each carotenoid was determined among 839 NHS participants, 804 of whom had the individual plasma carotenoids assayed in 2 blood samples collected approximately 10 years apart. These ICCs were: 0.53 for a-carotene, 0.50 for b-carotene, 0.60 for b-cryptoxanthin, and 0.61 for lutein/ zeaxanthin.
Expected ORs comparing extreme weighted multi-SNP score quintiles were determined by exponentiating the following formula: ðD Âb ÂĝÞ=ICC, whereb ¼ the b-coefficient for each continuous weighted multi-SNP score in relation to the relevant plasma carotenoid in units of natural log-transformed mg/L,ĝ ¼ the logistic regression coefficient for each continuous plasma carotenoid as quintile medians among controls in units of natural log-transformed mg/L in relation to breast cancer risk determined from a recalculation of (2), and D ¼ the difference in the median value among BPC3 controls of the relevant weighted multi-SNP score across extreme weighted multi-SNP score quintiles. P values for the test of the hypothesis that the expected and observed ORs are equal were determined from the z score for the difference between the natural log of the observed OR and the natural log of the expected OR where the standard error of the difference ¼ ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
This calculation assumes the estimates of the observed and expected ORs are independent. Although MEC, NHS, and WHS contributed to both estimates, several cohorts contributed to only one estimate (2) . We thus assumed adequate independence.
Results
Each SNP was in Hardy-Weinberg equilibrium among controls by cohort (all P > 0.05). Supplementary Table S2 includes characteristics of the participants by cohort and case-control status.
Individual SNP results
No SNP was associated with breast cancer overall or with specific subtypes defined by ER status (Supplementary Table S3) 
Multi-SNP scores
The multi-SNP scores were associated with plasma concentrations of a-and b-carotene, b-cryptoxanthin, lutein/zeaxanthin, and retinol (Supplementary Table  S1 ). The provitamin A carotenoid-weighted multi-SNP scores were positively correlated with each other and inversely correlated with the lutein/zeaxanthin-and retinol-weighted multi-SNP scores (Supplementary Table  S4 ). The distribution of breast cancer risk factors did not differ by the b-carotene-weighted multi-SNP score (Table 1) or the other carotenoid-weighted multi-SNP scores (data not shown). Median-weighted multi-SNP score values by quintile are included in Table 2 . No weighted multi-SNP score was associated with risk of overall, ER þ , ER À , or ER À /PR À (data not shown) breast cancer. The expected ORs comparing top and bottom quintiles of the weighted multi-SNP scores (data not shown) were not significantly different from the observed ORs presented in Table 2 . When excluding 2,825 cases with in situ or unknown stage, we observed significant positive and inverse associations comparing extreme quintiles of the a-carotene and retinol-weighted multi-SNP scores, respectively, in relation to ER À /PR À breast cancer, but the trends were nonsignificant. As there was an overlap in NHS subjects used to generate the weights for the multi-SNP score and the breast cancer association analysis, we reran the association analysis for breast cancer excluding the NHS subjects. The results did not change (data not shown).
There were significant or borderline-significant interactions between alcohol intake and the provitamin A carotenoid-and retinol-weighted multi-SNP scores in relation to ER þ breast cancer risk (Table 3) . We observed no significant interactions between alcohol intake and the weighted multi-SNP scores in relation to overall or ER À breast cancer risk (Supplementary Table S5 ). Significant interactions also were observed between the provitamin A carotenoid-and retinol-weighted multi-SNP scores and pack-years of smoking in relation to overall breast cancer risk (Table 4) . Results were similar for ER þ and ER À breast cancer risk although not all results were significant (Supplementary Table S6 ).
When we simultaneously included cross-product terms for each provitamin A carotenoid-or retinol-weighted multi-SNP score and both alcohol intake and pack-years of smoking in the models for total breast cancer, only the interaction terms with pack-years of smoking were significant (P ¼ 0.03 for all provitamin A carotenoid-weighted multi-SNP scores and 0.04 for the retinol-weighted multi-SNP score). Likelihood ratio tests comparing models with and without the 2 interaction terms were also significant or borderline-significant (P ¼ 0.03 for the provitamin A carotenoid-weighted multi-SNP scores and 0.05 for the retinol-weighted multi-SNP score). When limited to ER þ breast cancer cases, neither interaction term was significant, but the likelihood ratio tests comparing models with and without the 2 interaction terms were significant (P ¼ 0.03 for the a-carotene-weighted multi-SNP score and 0.04 for the b-carotene-, b-cryptoxanthin-, and retinol-weighted multi-SNP scores).
There were no significant interactions between the weighted multi-SNP scores and menopausal status, BMI, or smoking status in relation to total, ER þ , or ER À breast cancer risk.
Discussion
In this pooled analysis of 9,226 cases and 10,420 controls using a Mendelian Randomization approach to indirectly assess the hypothesis that higher carotenoid exposure is causally associated with lower risk of breast cancer, we did not observe significant associations between BCMO1 individual SNPs or weighted multi-SNP scores and breast cancer risk. Because the associations were nonsignificant, but expected ORs for each weighted multi-SNP score and breast cancer risk were not significantly different from the observed ORs, our null results neither support nor refute a causal association between carotenoids and breast cancer risk.
Our analysis was limited by the small number of genetic predictors of plasma carotenoid and retinol concentrations. The weighted multi-SNP scores were composed of 2 SNPs reported to be associated with b-carotene conversion efficiency and circulating b-carotene concentrations (10, 15, 16) . In a previous GWAS in the InCHIANTI study, one of these SNPs was also associated with circulating lutein to a similar magnitude and less strongly associated with circulating a-carotene, lycopene, and zeaxanthin (10). Associations with a-, b-carotene, and lutein/zeaxanthin were confirmed in the NHS (17) . However, to be of use, Mendelian Randomization requires a fairly strong association between the genetic variant and the exposure of causal interest (14) . The weighted multi-SNP scores explained 5.7% and 6.5% of the variation in plasma b-carotene and lutein/zeaxanthin, respectively, in the NHS (Supplementary Table S1 ). For a-carotene, b-cryptoxanthin, and retinol, the weighted multi-SNP scores only explained 0.2% to 1.4% of variation in the respective plasma biomarker concentrations in the NHS. Given the homeostasis of blood retinol concentrations in the absence of severely low liver stores (20) and the fact that liver vitamin A concentrations are lower in b-carotene-fed BCMO1 knockout mice (21, 22) , associations between SNPs in BCMO1 and retinol may be stronger in other tissues. Pleiotropy also may have limited the weighted multi-SNP scores as they were correlated with each other. Thus, while the weighted multi-SNP scores likely overcame confounding by noncarotenoid constituents of fruits and vegetables and lifestyle, they may have been confounded by each other. We therefore cannot necessarily attribute observed associations to a specific carotenoid or retinol, and associations may have been nullified if 2 biomarkers oppositely associated with a given weighted multi-SNP score were similarly associated with breast cancer risk.
Mendelian Randomization relies on 3 key assumptions. First, the genotype is associated with the intermediate phenotype (here, carotenoid levels). Second, there is no unmeasured common cause of genotype and the outcome (here, breast cancer). Third, every directed pathway from genotype to the outcome passes through the intermediate phenotype (23) . The use of the Mendelian Randomization approach also depends on the strength of the association between the exposure of causal interest and disease risk (14) . The strongest association observed in the recent pooled analysis was between circulating b-carotene and risk of ER 
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weighted multi-SNP score and plasma b-carotene in the NHS, our strongest expected OR was 0.83 for ER À breast cancer comparing extreme b-carotene-weighted multi-SNP score quintiles. On the basis of calculations provided by Schlesselman (24) , 355 ER À cases in the extreme b-carotene-weighted multi-SNP score quintiles, and a 8.6:1 control:case ratio, we had 37% power to detect an OR of 0.83, assuming a causal relation exists between circulating b-carotene and ER À breast cancer risk. To obtain 80% power, we would have needed 1,039 ER À cases and 8,909 controls in the extreme b-caroteneweighted multi-SNP score quintiles. The expected OR for overall breast cancer was 0.94 comparing extreme b-carotene-weighted multi-SNP score quintiles. With 2,811 cases in the extreme b-carotene-weighted multi-SNP score quintiles, and a 1.1:1 control:case ratio, we had 22% power to detect an OR of 0.94, assuming a causal relation exists between circulating b-carotene and breast cancer risk. To obtain 80% power, we would have needed 16,022 cases and 17,350 controls in the extreme b-carotene-weighted multi-SNP score quintiles. Future studies will thus require large sample sizes and/or use a genetic surrogate more strongly associated with circulating carotenoids.
We observed significant interactions between specific weighted multi-SNP scores and both alcohol intake and pack-years of smoking, but pleiotropy, common cooccurrence of alcohol intake and smoking, and multiple comparisons render interpretations speculative. Retinoic acid inhibits proliferation in ER þ breast cancer cell lines (25) , and chronic alcohol intake decreases hepatic retinoids and increases hepatic expression of BCMO1 in rats (26) . Thus, associations between the a-carotene and retinol-weighted multi-SNP scores (which were inversely correlated with each other) and ER þ breast cancer risk in women consuming !1 drink/d may be due to higher retinol requirements in these women instead of an adverse effect of a-carotene. We hypothesized carotenoids would protect more strongly against breast cancer risk in smokers due to their increased exposure to oxidative stress. As we conducted many tests, observed interactions may be chance findings and thus require confirmation.
In summary, this study does not provide evidence that genetic variants predicting circulating carotenoids are associated with breast cancer. Because a large-scale randomized trial of b-carotene for reduction of breast cancer risk is unlikely to occur given the outcome of previous b-carotene supplementation trials in relation to lung cancer (27, 28) , genetic studies may be the best option by which to further study causality in the associations between carotenoids and breast cancer. Future studies should therefore attempt to identify additional genetic surrogates for carotenoid exposure (29) .
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